The following is a summary of several registries currently in operation. These registries were established for the purpose of monitoring prenatal drug exposures for evidence of teratogenicity. Registry data are provided to supplement animal toxicology studies. Semi-annual interim reports of registry data are available to interested health care professionals. Health care professionals are asked to register patients and assist in providing follow-up information postpartum.
All information is confidential.
Enrolled women will be asked to provide through their doctors information about the health status of their infants. The findings will be analyzed to access the fetal risk from all AED in pregnancy. The registry site is based out of the Genetics and Teratology Unit at Massachusetts General Hospital, under the direction of Dr. Lewis Holmes. Infants and children with any type of birth defect or hemangiomas who were exposed in utero to CVS are being recruited. All expenses for participating will be provided.